The shares of an Indian Chemicals company engaged in manufacturing Pyridine, Picoline, Cynopyridine, and its derivatives have surged 13 percent from the previous closing price. The company’s financial results show robust Revenue growth of 48 percent Y-O-Y, and the Net profits are up by 358 percent
The shares of Resonance Specialities Ltd, with a market capitalization of Rs. 132.72 crores on Tuesday. Its shares are trading at a CMP of Rs 114.97, against the previous closing price of Rs 106.17. The stock has surged by 13 percent intraday to hit a high of Rs 120.00
What Happened
Resonance Specialities Ltd, a company involved in the manufacturing of Pyridine, Picoline, Cynopyridine, and derivatives of the same, announced its results for the Financial year ‘25. Its Revenue grew by 48 percent YoY from Rs 16.4 Crores in Q4FY24 to Rs 24.2 Crores in Q4FY25, and it has increased by close to 33 percent QoQ from Rs 18.2 Crores in Q3FY25 to Rs 24.2 Crores in Q4FY25.
Its Net Profit grew by 358 percent YoY from Rs. 0.67 Crores in Q4FY24 to Rs. 3.06 Crores in Q4FY25. The Net profits have grown by 173.2 percent QoQ from Rs. 1.12 Crores in Q3FY25 to Rs. 3.06 Crores in Q4FY25.
The company’s Earnings Before Interest, Depreciation, and Taxes (EBIDT) has also grown by 305 percent YOY from Rs 1.05 crores in Q4FY24 to Rs 4.25 crores in Q4FY25. Its EPS has also grown by 357 percent YOY from Rs. 0.58 in Q4FY24 to Rs. 2.65 in Q4FY25.
The company has declared a dividend of Re. 1 per share, 10 percent for the financial year 2024-25, subject to the approval of the Shareholders at the forthcoming Annual General Meeting.
About the company
Resonance Specialities Limited is manufacturing and marketing Pyridine and Pyridine derivatives, Picoline, Cynopyridine, and some bulk drugs. The Company’s plant is located in the Tarapur Industrial Zone near Mumbai, India. It has plants to manufacture Pyridines, Picolines, Lutidines, Collidines, Cyanopyridines, and various value-added products.
Written by Likesh babu s
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
